|
1
|
Tanaka S: Precision medicine based on
surgical oncology in the era of genome-scale analysis and genome
editing technology. Ann Gastroenterol Surg. 2:106–115.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Moghadam AR, Patrad E, Tafsiri E, Peng W,
Fangman B, Pluard TJ, Accurso A, Salacz M, Shah K, Ricke B, et al:
Ral signaling pathway in health and cancer. Cancer Med.
6:2998–3013. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Oxford G, Owens CR, Titus BJ, Foreman TL,
Herlevsen MC, Smith SC and Theodorescu D: RalA and RalB:
Antagonistic relatives in cancer cell migration. Cancer Res.
65:7111–7120. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Smith SC, Baras AS, Owens CR, Dancik G and
Theodorescu D: Transcriptional signatures of Ral GTPase are
associated with aggressive clinicopathologic characteristics in
human cancer. Cancer Res. 72:3480–3491. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ajani JA, Estrella JS, Chen Q, Correa AM,
Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, et al: Galectin-3
expression is prognostic in diffuse type gastric adenocarcinoma,
confers aggressive phenotype, and can be targeted by YAP1/BET
inhibitors. Br J Cancer. 118:52–61. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Saito F, Shimada H, Ogata H, Otsuka T,
Nemoto T, Shibuya K and Kaneko H: Detection of the early phase of
esophageal cancer progression into lamina propria mucosae by the
serum p53 antibody. Esophagus. 14:366–369. 2017.
|
|
7
|
Shimada H, Nagata M, Cho A, Takiguchi N,
Kainuma O, Soda H, Ikeda A, Nabeya Y, Yajima S, Yamamoto H, et al:
Long-term monitoring of serum p53 antibody after neoadjuvant
chemotherapy and surgery for esophageal adenocarcinoma: Report of a
case. Surg Today. 44:1957–1961. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Okada R, Shimada H, Otsuka Y, Tsuchiya M,
Ishii J, Katagiri T, Maeda T, Kubota Y, Nemoto T and Kaneko H:
Profiling of Serum Autoantibodies in Japanese Patients with
Hepatocellular Carcinoma. Toho J Medicine. 3:84–92. 2017.
|
|
9
|
Nanami T, Shimada H, Yajima S, Oshima Y,
Matsushita K, Nomura F, Nagata M, Tagawa M, Otsuka S, Kuwajima A
and Kaneko H: Clinical significance of serum autoantibodies against
Ras-like GTPases, RalA, in patients with esophageal squamous cell
carcinoma. Esophagus. 13:167–172. 2016.
|
|
10
|
Ushigome M, Nabeya Y, Soda H, Takiguchi N,
Kuwajima A, Tagawa M, Matsushita K, Koike J, Funahashi K and
Shimada H: Multi-panel assay of serum autoantibodies in colorectal
cancer. Int J Clin Oncol. 23:917–923. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kubota Y, Ogata H, Otsuka S, Kuwajima A,
Saito F and Shimada H: Presence of autoantibodies against Ras-like
GTPases in Serum-in stage I/II breast cancer. Toho J Medicine.
3:125–130. 2017.
|
|
12
|
Sun H, Shi JX, Zhang HF, Xing MT, Li P,
Dai LP, Luo CL, Wang X, Wang P, Ye H, et al: Serum autoantibodies
against a panel of 15 tumor-associated antigens in the detection of
ovarian cancer. Tumour Biol. 39(1010428317699132)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hoshino I, Nagata M, Takiguchi N, Nabeya
Y, Ikeda A, Yokoi S, Kuwajima A, Tagawa M, Matsushita K, Yajima S
and Shimada H: Panel of autoantibodies against multiple
tumor-associated antigens for detecting gastric cancer. Cancer Sci.
108:308–315. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Suzuki T, Funahashi K, Ushigome M, Koike
J, Nemoto T and Shimada H: Diagnostic and prognostic impact of
serum p53 antibody titration in colorectal cancer. Toho J Med.
3:107–115. 2017.
|
|
15
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th edition.
John Wiley & Sons, Hoboken, NJ, 2017.
|
|
17
|
Shimada H: p53 molecular approach to
diagnosis and treatment of esophageal squamous cell carcinoma. Ann
Gastroenterol Surg. 2:266–273. 2018.PubMed/NCBI View Article : Google Scholar
|
